Corporate Governance

Mr. Levy, 58, has served as our Chief Executive Officer and President since September 10, 2019 and was our Chief Financial Officer from December 31, 2019 until June 1, 2021.  Mr. Levy has also served on our Board since September 9, 2021.  Mr. Levy was a former investment banker with Cova Capital and was a capital market specialists. Prior to that, he was the president and CEO of Warlock Records Inc. and its related companies from its inception in 1985. While at Warlock, he led the successful turn-around of several financially distressed music companies as part of a roll up strategy. He has expertise in consumer products, marketing, television/radio advertising and direct to consumer sales.

As the CAO of Shutterstock, a leading global creative platform offering high-quality digital content, Mr. Ciardiello leads a global finance team responsible for SEC reporting, tax, internal audit, and general accounting. Since joining Shutterstock in 2016, he has led numerous financial transformation initiatives, improved reporting efficiency, and led efforts to streamline enterprise resource planning and financial operations. Prior to Shutterstock, Mr. Ciardiello held several finance leadership positions overseeing the redesign of the financial close process and implemented a global ERP system and has over 15 years of Big 4 public accounting experience.

Steven Glassman, 56, has served on our Board of Director since March 8, 2021. Since January 2018, Mr. Glassman has served in the role of Global Business Initiatives at Nephila Advisors, LLC, a Nashville, TN based firm focused on catastrophic reinsurance and weather risk transfer markets in connection with the capital markets. From 2010 to 2017, Mr. Glassman served as the Chief Management Officer of Nephila Capital Ltd. Mr. Glassman holds a Bachelor of Arts in Economics from Vanderbilt University.

Kevin Harris is Chief Operating Officer of Fountainhead Biomedical Holdings, Inc., the parent company of Sequence Life Science, Inc., NVISION Biomedical Technologies, Inc., and Cadaver Lab SA, LLC. Kevin brings more than 25 years of experience spanning asset management, capital markets, and private enterprise leadership. Over the course of his career, he has overseen more than $2 billion in assets for ultra-high-net-worth families and complex organizations. Prior to joining Fountainhead, Kevin served as Partner and Chief Investment Officer of O’Reilly Development Company, LLC, where he led investment strategy for the O’Reilly Family Office, and also oversaw asset management and capital structuring efforts for a diversified commercial real estate portfolio valued at more than $500 million. Kevin is a Chartered Financial Analyst (CFA) and holds a bachelor’s degree in accounting from The University of Texas at San Antonio.

Scott R. Henry, CFA, is a Managing Director, Senior Research Analyst at ROTH Capital Partners with 20 years of sell-side coverage in the pharmaceutical, biotechnology and medical device sectors. He has previously held positions with firms including Oppenheimer, Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co. Mr. Henry has received numerous awards, including rankings in the Wall Street Journal "Best on the Street" stock picking survey, Forbes/Zacks Investment Research "Best Analysts" for the drugs category and Forbes.com/StarMine rankings for earnings estimate accuracy. His investment views have been cited in the Wall Street Journal and the New York Times, and he has made frequent appearances on CNBC, CBS MarketWatch and Bloomberg. Mr. Henry attended the University of Rhode Island and received an M.B.A. with distinction from Cornell University.

Dr. Zeldis, 71, has served on our Board of Directors since April 1, 2020. Since April 2020, Dr. Zeldis has been serving as the executive chairman ViralClear Pharmaceuticals, Inc., a partially owned subsidiary of BioSig Technologies, Inc. (NASDAQ: BSGM), a company for which Dr. Zeldis has also been a member of the Board of Directors since May 2019. From 2016 to March 2019, Dr. Zeldis served as Chief Medical Officer and President of Clinical Research, Medical Affairs Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc. From 2014 until 2016, Dr. Zeldis served as chief executive officer of Celgene Global Health and chief medical officer of Celgene Corporation. Since June 2011, Dr. Zeldis has been a director of Soligenix, Inc. and PTC Therapeutics, Inc. He attended Brown University for an AB, MS, followed by Yale University for an MPhil, MD, and PhD in Molecular Biophysics and Biochemistry. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey.

Brian J. Kieser is the Founder and Chief Executive Officer of Fountainhead Biomedical Holdings, a platform focused on developing and commercializing advanced medical technologies across orthopedic devices, regenerative biologics, and manufacturing. The platform includes Nvision Biomedical Technologies, Sequence LifeScience, and Lockhill Advanced Manufacturing Technologies—each designed to address critical challenges in surgery, tissue healing, and medical device production. Brian previously held financial leadership roles across multiple industries and holds 14 patents related to medical device identification and traceability. Mr. Kieser earned a BBA in Accounting from the University of Texas at El Paso and is a Texas licensed CPA.